OTR Acquisition Corp. Shares Halted On Circuit Breaker
$OTRA
OTR Acquisition Corp. Shares Halted On Circuit Breaker
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb
Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c
Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202
4 - OTR Acquisition Corp. (0001821318) (Issuer)
4 - OTR Acquisition Corp. (0001821318) (Issuer)
4 - OTR Acquisition Corp. (0001821318) (Issuer)
15-12B - OTR Acquisition Corp. (0001821318) (Filer)
25-NSE - OTR Acquisition Corp. (0001821318) (Subject)
SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)
SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)
SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)